ATE137244T1 - N-oxycarbonyl substitutierte 5'-deoxy-5- fluorocytidin - Google Patents

N-oxycarbonyl substitutierte 5'-deoxy-5- fluorocytidin

Info

Publication number
ATE137244T1
ATE137244T1 AT93119349T AT93119349T ATE137244T1 AT E137244 T1 ATE137244 T1 AT E137244T1 AT 93119349 T AT93119349 T AT 93119349T AT 93119349 T AT93119349 T AT 93119349T AT E137244 T1 ATE137244 T1 AT E137244T1
Authority
AT
Austria
Prior art keywords
radical
formula
fluorocytidine
deoxy
integer
Prior art date
Application number
AT93119349T
Other languages
English (en)
Inventor
Motohiro Arasaki
Hideo Ishitsuka
Isami Kuruma
Masanori Miwa
Chikako Murasaki
Nobuo Shimma
Isao Umeda
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8210304&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE137244(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE137244T1 publication Critical patent/ATE137244T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT93119349T 1992-12-18 1993-12-01 N-oxycarbonyl substitutierte 5'-deoxy-5- fluorocytidin ATE137244T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP92121538 1992-12-18

Publications (1)

Publication Number Publication Date
ATE137244T1 true ATE137244T1 (de) 1996-05-15

Family

ID=8210304

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93119349T ATE137244T1 (de) 1992-12-18 1993-12-01 N-oxycarbonyl substitutierte 5'-deoxy-5- fluorocytidin

Country Status (41)

Country Link
US (1) US5472949A (de)
EP (1) EP0602454B1 (de)
JP (1) JP2501297B2 (de)
KR (1) KR100347218B1 (de)
CN (1) CN1035617C (de)
AT (1) ATE137244T1 (de)
AU (1) AU671491B2 (de)
BG (1) BG61485B1 (de)
BR (1) BR9305089A (de)
CA (1) CA2103324C (de)
CZ (1) CZ284788B6 (de)
DE (1) DE69302360T2 (de)
DK (1) DK0602454T3 (de)
EE (1) EE03086B1 (de)
ES (1) ES2086856T3 (de)
FI (1) FI112365B (de)
GE (1) GEP20074251B (de)
GR (1) GR3020286T3 (de)
HK (1) HK1005875A1 (de)
HR (1) HRP931430B1 (de)
HU (2) HU218291B (de)
IL (1) IL108000A0 (de)
IS (1) IS4108A (de)
LT (1) LT3115B (de)
LV (1) LV10625B (de)
MY (1) MY109282A (de)
NO (1) NO300066B1 (de)
NZ (1) NZ250414A (de)
PH (1) PH30168A (de)
PL (1) PL174100B1 (de)
RO (1) RO112619B1 (de)
RU (2) RU2493162C1 (de)
SA (1) SA93140409B1 (de)
SI (1) SI9300648B (de)
SK (1) SK281403B6 (de)
SV (1) SV1993000080A (de)
TW (1) TW372239B (de)
UA (1) UA39158C2 (de)
UY (1) UY23697A1 (de)
YU (1) YU49411B (de)
ZA (1) ZA939293B (de)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5476932A (en) * 1994-08-26 1995-12-19 Hoffmann-La Roche Inc. Process for producing N4-acyl-5'-deoxy-5-fluorocytidine derivatives
EP0882734B1 (de) * 1997-06-02 2009-08-26 F. Hoffmann-La Roche Ag 5-Deoxy-Cytidin-Derivate
NZ330360A (en) * 1997-06-02 1999-03-29 Hoffmann La Roche 5'-deoxy-cytidine derivatives, their manufacture and use as antitumoral agents
US6005098A (en) * 1998-02-06 1999-12-21 Hoffmann-La Roche Inc. 5'deoxycytidine derivatives
ID30046A (id) * 1998-09-25 2001-11-01 Warner Lambert Co Kemoterapi kanker dengan asetildinalina digabung dengan gemsitabina, kapestabina atau kisplatin
US20070122481A1 (en) * 1998-11-02 2007-05-31 Elan Corporation Plc Modified Release Compositions Comprising a Fluorocytidine Derivative for the Treatment of Cancer
US20080113025A1 (en) * 1998-11-02 2008-05-15 Elan Pharma International Limited Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
NZ520593A (en) * 2000-02-28 2004-10-29 Aventis Pharma S A composition comprising camptothecin and a pyrimidine derivative for the treatment of cancer
AU2001246863A1 (en) * 2000-04-11 2001-10-23 Sayuri Yamada Curcumin compositions
KR100730768B1 (ko) * 2000-08-09 2007-06-21 코오롱생명과학 주식회사 5'-데옥시-ｎ-알킬옥시카르보닐-5-플루오로사이토신-5'-카르복실산 및 그 유도체와 이들의 제조방법
KR100631754B1 (ko) * 2000-08-09 2006-10-09 주식회사 코오롱 Ｎ-알킬옥시카르보닐-5-플루오로사이토신 유도체 및 그의제조방법
GB0113374D0 (en) * 2001-06-04 2001-07-25 Jerram Clare Washing line umbrella
KR20040078123A (ko) * 2002-01-14 2004-09-08 노파르티스 아게 에포틸론 및 대사길항물질을 포함하는 조합물
EP2316468A1 (de) 2002-02-22 2011-05-04 Shire LLC Abgabesystem und Verfahren zum Schutz und zur Verabreichung von Dextroamphetamin
EP1562601A1 (de) * 2002-11-15 2005-08-17 Warner-Lambert Company LLC Kombinationschemotherapie von einem mek hemmer und capecitabine zur behandlung von krebs
EP1631278A4 (de) * 2003-05-20 2006-09-20 Aronex Pharmaceuticals Inc Kombinationschemotherapie mit capecitabin und einem liposomalen platinkomplex
CA2544320A1 (en) * 2003-11-13 2005-06-02 Pharma Mar, S.A.U. Method of treating cancer using a combination comprising et-743 and 5-fluorouracil
ATE402185T1 (de) * 2003-12-22 2008-08-15 Hoffmann La Roche Verfahren für fluorcytidinderivate
CN113952459B (zh) 2005-02-03 2025-02-11 综合医院公司 治疗吉非替尼耐药性癌症的方法
EP1868608A2 (de) * 2005-04-01 2007-12-26 F. Hoffmann-Roche AG Verfahren zur verabreichung von capecitabin
SG164368A1 (en) 2005-07-18 2010-09-29 Bipar Sciences Inc Treatment of cancer
US20080292729A1 (en) 2005-07-21 2008-11-27 Nuvo Research Inc. Stabilized Chlorite Solutions in Combination with Fluoropyrimidines for Cancer Treatment
CN103110948A (zh) 2005-11-04 2013-05-22 惠氏公司 mTOR抑制剂、赫赛汀和/或HKI-272的抗肿瘤组合
ATE525374T1 (de) 2005-12-13 2011-10-15 Incyte Corp Heteroarylsubstituierte pyrroloä2,3-büpyridine und pyrroloä2,3-büpyrimidine als januskinaseinhibitoren
US20100160442A1 (en) * 2006-07-18 2010-06-24 Ossovskaya Valeria S Formulations for cancer treatment
US20080085310A1 (en) * 2006-10-06 2008-04-10 Maria Oksana Bachynsky Capecitabine rapidly disintegrating tablets
CN100425617C (zh) * 2006-10-31 2008-10-15 浙江海正药业股份有限公司 一种含氟嘧啶类化合物烷氧羰酰化的方法
ITMI20070435A1 (it) 2007-03-05 2008-09-06 Innovate Biotechnology Srl 2',3'-di-o-acil-5-fluoronucleosidi
BRPI0810067A2 (pt) * 2007-04-20 2014-10-21 Reddys Lab Ltd Dr Processo para a preparação de capecitabina
EP2164856A1 (de) * 2007-06-01 2010-03-24 Synthon B.V. Mit der herstellung von capecitabin in zusammenhang stehende verfahren
ES2467665T5 (es) 2007-06-13 2022-11-03 Incyte Holdings Corp Sales del inhibidor de cinasas Janus (R)-3-(4-(7H-pirrolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il)-3-ciclopentilpropanonitrilo
US7842675B2 (en) * 2007-09-15 2010-11-30 Protia, Llc Deuterium-enriched capecitabine
WO2009042064A2 (en) 2007-09-21 2009-04-02 Nektar Therapeutics Al, Corporation Oligomer-nucleoside phosphate conjugates
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
KR101013312B1 (ko) * 2007-11-19 2011-02-09 한미홀딩스 주식회사 카페시타빈의 제조방법 및 이에 사용되는 β-아노머가강화된 트리알킬카보네이트 화합물의 제조방법
AR064165A1 (es) 2007-12-06 2009-03-18 Richmond Sa Com Ind Y Financie Un procedimiento para la preparacion de capecitabina e intermediarios utilizables en dicho procedimiento
WO2009088989A1 (en) * 2008-01-03 2009-07-16 Plus Chemicals, S.A. Process for the preparation of capecitabine
US20090311335A1 (en) * 2008-06-12 2009-12-17 Scott Jenkins Combination of a triptan and an nsaid
CN102641270A (zh) 2008-06-17 2012-08-22 惠氏有限责任公司 含有hki-272和长春瑞滨的抗肿瘤组合
HUE032958T2 (hu) 2008-08-04 2017-11-28 Wyeth Llc 4-Anilino-3-ciano-kinolinok és capecitabin antineoplasztikus kombinációi
WO2010065586A2 (en) * 2008-12-02 2010-06-10 Dr. Reddy's Laboratories Ltd. Preparation of capecitabine
EP2393472B1 (de) * 2008-12-05 2019-06-05 NanoMed Holdings Pty Ltd Amphiphile prodrugs
LT3000467T (lt) 2009-04-06 2023-04-11 Wyeth Llc Krūties vėžio gydymo schema naudojant neratinibą
FR2945211A1 (fr) 2009-05-06 2010-11-12 Sanofi Aventis Combinaison antitumorale comprenant la cabazitaxel et la capecitabine
JP6172939B2 (ja) 2009-05-22 2017-08-02 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｊａｋ阻害薬としての３−［４−（７ｈ−ピロロ［２，３−ｄ］ピリミジン−４−イル）−１ｈ−ピラゾール−１−イル］オクタン−またはヘプタン−ニトリル
KR20120037932A (ko) * 2009-07-23 2012-04-20 시노팜 타이완 리미티드 플루오로시티딘 유도체를 제조하는 방법
WO2011067588A1 (en) 2009-12-04 2011-06-09 Generics [Uk] Limited Cyclic sulphinyl esters of cytidine
WO2011104540A1 (en) * 2010-02-24 2011-09-01 Generics [Uk] Limited One step process for the preparation of capecitabine
PE20130038A1 (es) 2010-03-10 2013-01-28 Incyte Corp Derivados de piperidin-4-il azetidina como inhibidores de jak1
PL3117709T3 (pl) 2010-03-12 2019-01-31 Genzyme Corporation Terapia skojarzona do leczenia raka piersi
KR102303885B1 (ko) 2010-05-21 2021-09-24 인사이트 홀딩스 코포레이션 Ｊａｋ 저해제에 대한 국소 제형
CN102260309B (zh) * 2010-05-24 2014-10-22 重庆福安药业(集团)股份有限公司 一种高纯度卡培他滨的制备方法
EA026201B1 (ru) 2010-11-19 2017-03-31 Инсайт Холдингс Корпорейшн Циклобутилзамещенные производные пирролопиридина и пирролопиримидина как ингибиторы jak
CN102558262A (zh) * 2010-12-23 2012-07-11 天津泰普药品科技发展有限公司 一种高纯度卡培他滨的制备方法
CA2839767A1 (en) 2011-06-20 2012-12-27 Incyte Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
CN102266303A (zh) * 2011-07-07 2011-12-07 程雪翔 一种卡培他滨药用组合物及其制备方法
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
CN102516338B (zh) * 2011-12-09 2014-04-02 海南锦瑞制药股份有限公司 一种卡培他滨化合物、其药物组合物及其制备方法
TWI560195B (en) * 2012-01-13 2016-12-01 Pharmaessentia Corp Novel synthesis of 5-deoxy-5'-fluorocytidine compounds
RS62329B1 (sr) 2012-11-15 2021-10-29 Incyte Holdings Corp Dozni oblici ruksolitiniba sa produženim vremenom oslobađanja
TR201820520T4 (tr) 2013-03-06 2019-01-21 Incyte Holdings Corp Bir jak inhibitörü yapmaya yönelik prosesler ve ara ürünler.
DK3030227T3 (da) 2013-08-07 2020-04-20 Incyte Corp Vedvarende frigivelses-doseringsformer for en jak1-inhibitor
WO2015026818A1 (en) * 2013-08-20 2015-02-26 Incyte Corporation Survival benefit in patients with solid tumors with elevated c-reactive protein levels
EP2883959A1 (de) 2013-12-13 2015-06-17 Plasmia Biotech, S.L. Enzymatische Herstellung von Cytosin-Nukleosidanaloga
CN103897006A (zh) * 2013-12-18 2014-07-02 吉林修正药业新药开发有限公司 一种卡培他滨异构体的制备方法
US9937261B2 (en) 2014-06-09 2018-04-10 Lipomedix Pharmaceuticals Ltd. Combination therapy comprising a liposomal prodrug of mitomycin C and radiotherapy
CN104530164A (zh) * 2014-12-31 2015-04-22 辰欣药业股份有限公司 一种卡培他滨的合成工艺
KR20160117060A (ko) 2015-03-31 2016-10-10 이승주 유아용 탁자
CN105646625B (zh) * 2015-12-29 2019-06-11 江苏吴中医药集团有限公司 一种卡培他滨的制备方法
WO2018129533A1 (en) 2017-01-09 2018-07-12 Shuttle Pharmaceuticals, Llc Selective histone deacetylase inhibitors for the treatment of human disease
US11584733B2 (en) 2017-01-09 2023-02-21 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
TR201702500A2 (tr) * 2017-02-20 2017-07-21 Anadolu Ueniversitesi Serani̇b-2?ni̇n akci̇ğer kanseri̇ ve meme kanseri̇ni̇n tedavi̇si̇nde kullanimi
US10435429B2 (en) 2017-10-03 2019-10-08 Nucorion Pharmaceuticals, Inc. 5-fluorouridine monophosphate cyclic triester compounds
WO2019113487A1 (en) 2017-12-08 2019-06-13 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
US11407723B2 (en) 2018-01-09 2022-08-09 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
EP3752511A4 (de) 2018-01-10 2021-12-29 Nucorion Pharmaceuticals, Inc. Phosphor(n)amidatacetal und phosph(on)atalcetalverbindungen
US11427550B2 (en) 2018-01-19 2022-08-30 Nucorion Pharmaceuticals, Inc. 5-fluorouracil compounds
CN111801339B (zh) * 2018-01-19 2025-06-24 纽科利制药公司 5-氟尿嘧啶化合物
WO2019152374A1 (en) 2018-01-30 2019-08-08 Incyte Corporation Processes for preparing (1 -(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one)
CA3095487A1 (en) 2018-03-30 2019-10-03 Incyte Corporation Treatment of hidradenitis suppurativa using jak inhibitors
AU2020207026A1 (en) 2019-01-11 2021-07-29 Lipomedix Pharmaceuticals Ltd. Liposome composition comprising liposomal prodrug of mitomycin C and method of manufacture
MX2022000573A (es) 2019-07-17 2022-02-10 Nucorion Pharmaceuticals Inc Compuestos ciclicos de desoxirribonucleotido.
KR20230004716A (ko) 2020-04-21 2023-01-06 리간드 파마슈티칼스 인코포레이티드 뉴클레오티드 프로드러그 화합물
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
CN116368143A (zh) 2020-08-31 2023-06-30 埃莫里大学 5'-取代的单磷酸核苷、其前药及其相关用途
WO2023177894A1 (en) 2022-03-18 2023-09-21 Ideaya Biosciences, Inc. Combination therapy comprising a mat2a inhibitor and an antimetabolite agent
EP4382093B1 (de) 2022-12-05 2025-08-27 a Fine House S.A. Orale suspensionen mit capecitabin

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1135258A (en) * 1979-06-15 1982-11-09 Richard D'souza Process for the preparation of 5'deoxy-5-fluorouridine
EP0184365B1 (de) * 1984-12-04 1993-08-04 Eli Lilly And Company Tumorbehandlung bei Säugetieren
CA1327358C (en) * 1987-11-17 1994-03-01 Morio Fujiu Fluoro cytidine derivatives

Also Published As

Publication number Publication date
KR100347218B1 (ko) 2003-01-24
GR3020286T3 (en) 1996-09-30
NO300066B1 (no) 1997-04-01
BR9305089A (pt) 1994-07-05
RO112619B1 (ro) 1997-11-28
US5472949A (en) 1995-12-05
RU2458932C2 (ru) 2012-08-20
LT3115B (en) 1994-12-27
FI935616L (fi) 1994-06-19
CZ273193A3 (en) 1994-07-13
PH30168A (en) 1997-01-21
RU2493162C1 (ru) 2013-09-20
NO934671D0 (no) 1993-12-17
HU211965A9 (en) 1996-01-29
IS4108A (is) 1994-06-19
EP0602454A1 (de) 1994-06-22
EP0602454B1 (de) 1996-04-24
DK0602454T3 (da) 1996-07-29
HU9303525D0 (en) 1994-04-28
CZ284788B6 (cs) 1999-03-17
TW372239B (en) 1999-10-21
HU218291B (en) 2000-07-28
LTIP1627A (en) 1994-07-15
HK1005875A1 (en) 1999-01-29
CA2103324C (en) 1997-12-23
JPH06211891A (ja) 1994-08-02
UY23697A1 (es) 1994-06-08
NZ250414A (en) 1995-12-21
SA93140409B1 (ar) 2004-07-24
SK281403B6 (sk) 2001-03-12
CN1094056A (zh) 1994-10-26
DE69302360T2 (de) 1996-10-31
CA2103324A1 (en) 1994-06-19
FI112365B (fi) 2003-11-28
ZA939293B (en) 1994-06-18
NO934671L (no) 1994-06-20
SI9300648B (sl) 2000-06-30
AU5069093A (en) 1994-06-30
JP2501297B2 (ja) 1996-05-29
ES2086856T3 (es) 1996-07-01
SV1993000080A (es) 1996-01-26
SI9300648A (en) 1994-09-30
SK144493A3 (en) 1994-10-05
BG61485B1 (bg) 1997-09-30
PL301541A1 (en) 1994-06-27
MY109282A (en) 1996-12-31
PL174100B1 (pl) 1998-06-30
DE69302360D1 (de) 1996-05-30
LV10625B (en) 1996-04-20
KR940014428A (ko) 1994-07-18
LV10625A (lv) 1995-04-20
GEP20074251B (en) 2007-12-10
HRP931430A2 (en) 1998-06-30
RU2135511C1 (ru) 1999-08-27
HRP931430B1 (en) 1999-08-31
HUT65757A (en) 1994-07-28
EE03086B1 (et) 1998-04-15
AU671491B2 (en) 1996-08-29
BG98304A (bg) 1994-01-03
CN1035617C (zh) 1997-08-13
UA39158C2 (uk) 2001-06-15
YU77993A (sh) 1996-10-18
FI935616A0 (fi) 1993-12-14
IL108000A0 (en) 1994-04-12
YU49411B (sh) 2006-01-16

Similar Documents

Publication Publication Date Title
DE69302360D1 (de) N-Oxycarbonyl substitutierte 5'-Deoxy-5-Fluorocytidin
RU93056196A (ru) N-карбонилзамещенные 5'-дезокси-5-фторцитидина
GR3020150T3 (en) Benzylidene azolyl methyl cycloalkane and its use as a fungicide
DE68905627D1 (de) Hydrophile sauerstoffdurchlaessige polymere.
HU9203016D0 (en) New taxane compounds substituted with alkoxy and pharmaceutical preparatives containing these compounds
ATE157352T1 (de) Von hydroxylaminen abgeleitete n,n'-substituierte imidocarbonimiddiamide
CA2065978A1 (en) Organosilicon compounds containing (meth)acryloxy groups, their preparation and use
TW216770B (de)
EP0401715A3 (de) Aminoketonverbindungen
ATE67231T1 (de) Klebstoff.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification